Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy (STOP-HE Study)
- Conditions
- neuropsychiatric abnormalities in patients with liver dysfunction/Brain dysfunction directly due to liver dysfunction10014623
- Registration Number
- NL-OMON42053
- Lead Sponsor
- Ocera Therapeutics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 7
* 18*75 years with HE admitted to hospital (eg, via emergency department or direct admission, etc);* Evidence of/known cirrhosis * The diagnosis of liver cirrhosis will be based on clinical, radiological, or histological criteria;* Hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis;* Venous ammonia greater than the upper limit of normal at Screening;* Acute HE episode defined by Stage * 2 (Hepatic Encephalopathy Staging Tool, Appendix A) at both Screening and baseline (pre-randomization). At the end of a prerequisite minimum 12-hour interval from hospital HE diagnosis to start of Screening patients must still be clearly overtly encephalopathic and during the Screening/Baseline Period have no improvement (decrease in Hepatic Encephalopathy Stage). During the 12-hour pre-Screening period in order to qualify the patient must consistently manifest hepatic encephalopathy that is clearly overt and equivalent to at least Stage 2 using the Hepatic Encephalopathy Staging Tool (Appendix A). ;* Patients with transjugular intrahepatic portosystemic shunt (TIPS) are allowed ;* Women of child-bearing potential must have negative serum pregnancy test
* Not expected to survive 2 weeks (note patients with malignancy, e.g. hepatocellular carcinoma, exceeding this life expectancy may enroll);* Type 1 hepatorenal syndrome characterized by rapidly progressive reduction in renal function as defined by a doubling of the initial serum creatinine to a level > 3 mg/dL or a 50% reduction of the initial 24-hour creatinine clearance to a level <20 mL/min in less than 2 weeks.;* Hyponatremia (sodium <125 mmol/L);* Renal failure with serum creatinine > 3 mg/dL (265.2 µmol/L) or need for hemodialysis, peritoneal dialysis, or continuous venovenous hemofiltration at Screening;* New York Heart Association (NYHA) Class 3 or 4 congestive heart failure or overt clinical signs of congestive heart failure;* Patients requiring mechanical ventilation may enroll if they are electively intubated only for airway protection (to prevent aspiration) due to severe HE and do not require ongoing sedation. Transitory intubation with sedation for specific procedure/intervention anticipated to be < 24 hours is allowed. The following ventilator settings would exclude a patient: (a) fraction of inspired oxygen (FiO2) > 0.5 (> 50% oxygen); (b) positive end-expiratory pressure (PEEP) > 10 cm H2O (water). The intent is to exclude patients requiring intubation for respiratory failure or severe pneumonia. Note continuous positive airway pressure (CPAP) is allowed.;* Any prior stroke with cognitive sequelae;* Acute alcoholic hepatitis (current hospital admission);* Schizophrenia, dementia, or other severe psychiatric disorders that would interfere with evaluation of hepatic encephalopathy;* Presentation to hospital with acute alcohol or drug intoxication (patients with alcoholic liver disease/cirrhosis due to alcohol are allowed). Inebriated patients and those with acute effects of alcohol at presentation, by immediate prior history, overall clinical evaluation, or blood alcohol level * 1.6 g/L (0.16% w/v, 160 mg/dL, 34.74 mmol/L) are excluded. Patients with symptoms of serious alcohol withdrawal at either Screening or Baseline are excluded.;* Patients with gastrointestinal bleeding may enroll. However, active upper gastrointestinal bleeding at the time of enrollment that has not been addressed by definitive endoscopic treatment or appropriate medical therapy and remains uncontrolled (requiring > 2 units packed red blood cells per day on a continuing ongoing basis) will exclude a patient; patients whom the physician considers likely to die of gastrointestinal bleeding should be excluded. Those with bleeding from portal hypertensive gastropathy may enroll provided they are within above confines.;* Hemodynamic instability, defined as a mean arterial pressure of <60 mm Hg and/or evidence of poor organ perfusion or the use of more than one (1) vasopressor to support blood pressure. Terlipressin, vasopressin (and analogs), and octreotide (and somatostatin analogs) are allowed to address complex vascular dynamic issues specific to this population (eg, variceal bleeding, renal perfusion). However, if more than one (1) vasopressor is being given for hemodynamic support of unstable mean arterial pressure (ie, implying shock and sequelae) this makes the patient ineligible. ;* Corrected QT interval calculated using Fridericia*s formula (QTcF) > 500 msec at screening ;* Concomitant administration of drugs known to interfere with renal excretion of phenylacetylglutamine (PAGN), such as probenecid. Use of L-ornithine L-aspartate and neo
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective of this study is the following:<br /><br>**To evaluate the efficacy of OCR-002 for treatment of an acute hepatic<br /><br>encephalopathy<br /><br>episode in cirrhotic patients requiring hospitalization<br /><br>**To evaluate the safety and tolerability of OCR-002 in hospitalized cirrhotic<br /><br>patients with<br /><br>an acute episode of hepatic encephalopathy</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary objectives include the following:<br /><br>**To confirm the pharmacokinetic (PK) profile of OCR-002 in this patient<br /><br>population<br /><br>**To assess the kinetics of reduction of plasma ammonia with OCR-002 and<br /><br>excretion of<br /><br>phenylacetylglutamine (PAGN) in urine</p><br>